Literature DB >> 19580781

Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease.

Sonu Kumar1, Anita Sarkar, Durai Sundar.   

Abstract

Understanding alpha-synuclein in terms of fibrillization, aggregation, solubility and stability is fundamental in Parkinson's disease (PD). The three familial mutations, namely, A30P, E46K and A53T cause PD because the hydrophobic regions in alpha-synuclein acquire beta-sheet configuration, and have a propensity to fibrillize and form amyloids that cause cytotoxicity and neurodegeneration. On simulating the native form and mutants (A30P, E46K and A53T) of alpha-synuclein in water solvent, clear deviations are observed in comparison to the all-helical 1XQ8 PDB structure. We have identified two crucial residues, (40)Val and (74)Val, which play key roles in beta-sheet aggregation in the hydrophobic regions 36-41 and 68-78, respectively, leading to fibrillization and amyloidosis in familial (A53T) PD. We have also identified V40D_V74D, a double mutant of A53T (the most amyloidogenic mutant). The simultaneous introduction of these two mutations in A53T nearly ends its aggregation propensity, increases its solubility and positively enhances its thermodynamic stability.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19580781     DOI: 10.1016/j.bbrc.2009.07.008

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  A53T mutant α-synuclein fibrils formed in macrophage are spread to neurons.

Authors:  Shogo Moriya; Michiko Hanazono; Takeshi Fukuhara; Katsuro Iwase; Nobutaka Hattori; Masaki Takiguchi
Journal:  Cell Mol Life Sci       Date:  2022-04-10       Impact factor: 9.261

2.  Structures of the E46K mutant-type α-synuclein protein and impact of E46K mutation on the structures of the wild-type α-synuclein protein.

Authors:  Olivia Wise-Scira; Aquila Dunn; Ahmet K Aloglu; Isin T Sakallioglu; Orkid Coskuner
Journal:  ACS Chem Neurosci       Date:  2013-01-30       Impact factor: 4.418

3.  Structures and free energy landscapes of the wild-type and A30P mutant-type α-synuclein proteins with dynamics.

Authors:  Olivia Wise-Scira; Ahmet Kemal Aloglu; Aquila Dunn; Isin Tuna Sakallioglu; Orkid Coskuner
Journal:  ACS Chem Neurosci       Date:  2013-01-30       Impact factor: 4.418

4.  Structures and free energy landscapes of the A53T mutant-type α-synuclein protein and impact of A53T mutation on the structures of the wild-type α-synuclein protein with dynamics.

Authors:  Orkid Coskuner; Olivia Wise-Scira
Journal:  ACS Chem Neurosci       Date:  2013-05-17       Impact factor: 4.418

Review 5.  α-Synuclein: An All-Inclusive Trip Around its Structure, Influencing Factors and Applied Techniques.

Authors:  Nicolò Bisi; Lucia Feni; Kaliroi Peqini; Helena Pérez-Peña; Sandrine Ongeri; Stefano Pieraccini; Sara Pellegrino
Journal:  Front Chem       Date:  2021-07-07       Impact factor: 5.221

Review 6.  The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease.

Authors:  Elizabeth A Mazzio; Fran Close; Karam F A Soliman
Journal:  Int J Mol Sci       Date:  2011-01-17       Impact factor: 5.923

7.  Identification of novel autophagic Radix Polygalae fraction by cell membrane chromatography and UHPLC-(Q)TOF-MS for degradation of neurodegenerative disease proteins.

Authors:  An-Guo Wu; Vincent Kam-Wai Wong; Wu Zeng; Liang Liu; Betty Yuen-Kwan Law
Journal:  Sci Rep       Date:  2015-11-24       Impact factor: 4.379

8.  Potential Role of Caffeine in the Treatment of Parkinson's Disease.

Authors:  Mohsin H K Roshan; Amos Tambo; Nikolai P Pace
Journal:  Open Neurol J       Date:  2016-07-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.